drugset
drugset / Trial / NCT05698199

Study to Evaluate the Safety, Tolerability, Immunogenicity and Preliminary Efficacy of ITI-1001 In Patients With Newly Diagnosed Glioblastoma (GBM)

NCT05698199 ↗

Phase 1 Completed 10 enrolled Immunomic Therapeutics, Inc.
NaSingle-groupOpen-labelTreatment

Summary

This Phase I clinical trial will evaluate the safety, tolerability, immunogenicity, and preliminary efficacy of 8 mg ITI-1001 in participants with newly diagnosed glioblastoma (GBM).

Timeline

Start
2023-08-21
Primary completion
2026-02-11
Completion
2026-06-01

Drugs

EvaluationDrugModalityDoseRoute
Subject ITI-1001 Vaccine 8 mg Intramuscular

Indications

glioblastoma